These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 23486687

  • 21. Alpha Internexin: A Surrogate Marker for 1p/19q Codeletion and Prognostic Marker in Anaplastic (WHO grade III) Gliomas.
    Rajmohan KS, Sugur HS, Shwetha SD, Pandey P, Arivazhagan A, Santosh V.
    Neurol India; 2020; 68(4):832-837. PubMed ID: 32859823
    [Abstract] [Full Text] [Related]

  • 22. Morphologically, genetically and spatially mixed astrocytoma and oligodendroglioma; chronological acquisition of 1p/19q codeletion and CDKN2A deletion: a case report.
    Takami H, Mukasa A, Takayanagi S, Koike T, Matsuura R, Ikemura M, Ushiku T, Yoshikawa G, Shibahara J, Tanaka S, Saito N.
    Brain Tumor Pathol; 2023 Jan; 40(1):26-34. PubMed ID: 36572828
    [Abstract] [Full Text] [Related]

  • 23. Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach.
    Rajmohan KS, Sugur HS, Shwetha SD, Ramesh A, Thennarasu K, Pandey P, Arivazhagan A, Santosh V.
    J Clin Pathol; 2016 Aug; 69(8):686-94. PubMed ID: 26743027
    [Abstract] [Full Text] [Related]

  • 24. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.
    Gorlia T, Delattre JY, Brandes AA, Kros JM, Taphoorn MJ, Kouwenhoven MC, Bernsen HJ, Frénay M, Tijssen CC, Lacombe D, van den Bent MJ.
    Eur J Cancer; 2013 Nov; 49(16):3477-85. PubMed ID: 23896377
    [Abstract] [Full Text] [Related]

  • 25. Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.
    Figarella-Branger D, Mokhtari K, Dehais C, Jouvet A, Uro-Coste E, Colin C, Carpentier C, Forest F, Maurage CA, Vignaud JM, Polivka M, Lechapt-Zalcman E, Eimer S, Viennet G, Quintin-Roué I, Aubriot-Lorton MH, Diebold MD, Loussouarn D, Lacroix C, Rigau V, Laquerrière A, Vandenbos F, Michalak S, Sevestre H, Peoch M, Labrousse F, Christov C, Kemeny JL, Chenard MP, Chiforeanu D, Ducray F, Idbaih A, POLA Network.
    Neuro Oncol; 2014 Sep; 16(9):1244-54. PubMed ID: 24723566
    [Abstract] [Full Text] [Related]

  • 26. Role of 1p/19q Codeletion in Diffuse Low-grade Glioma Tumour Prognosis.
    Familiari P, Lapolla P, Picotti V, Palmieri M, Pesce A, Carosi G, Relucenti M, Nottola S, Gianno F, Minasi S, Antonelli M, Frati A, Santoro A, D'Andrea G, Bruzzaniti P, LA Pira B.
    Anticancer Res; 2023 Jun; 43(6):2659-2670. PubMed ID: 37247932
    [Abstract] [Full Text] [Related]

  • 27. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
    Vogelbaum MA, Berkey B, Peereboom D, Macdonald D, Giannini C, Suh JH, Jenkins R, Herman J, Brown P, Blumenthal DT, Biggs C, Schultz C, Mehta M.
    Neuro Oncol; 2009 Apr; 11(2):167-75. PubMed ID: 18779504
    [Abstract] [Full Text] [Related]

  • 28. Prognosis of oligodendroglial tumor with ring enhancement showing central necrotic portion.
    Choi KY, Jung TY, Jung S, Kim YH, Moon KS, Kim IY, Kang SS, Lee KH.
    J Neurooncol; 2011 May; 103(1):103-10. PubMed ID: 20737192
    [Abstract] [Full Text] [Related]

  • 29. Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas.
    Lin AL, Liu J, Evans J, Leuthardt EC, Rich KM, Dacey RG, Dowling JL, Kim AH, Zipfel GJ, Grubb RL, Huang J, Robinson CG, Simpson JR, Linette GP, Chicoine MR, Tran DD.
    Neuro Oncol; 2014 Jan; 16(1):123-30. PubMed ID: 24285548
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis.
    Figarella-Branger D, Mokhtari K, Colin C, Uro-Coste E, Jouvet A, Dehais C, Carpentier C, Villa C, Maurage CA, Eimer S, Polivka M, Vignaud JM, Laquerriere A, Sevestre H, Lechapt-Zalcman E, Quintin-Roué I, Aubriot-Lorton MH, Diebold MD, Viennet G, Adam C, Loussouarn D, Michalak S, Rigau V, Heitzmann A, Vandenbos F, Forest F, Chiforeanu D, Tortel MC, Labrousse F, Chenard MP, Nguyen AT, Varlet P, Kemeny JL, Levillain PM, Cazals-Hatem D, Richard P, Delattre JY, POLA Network.
    Brain Pathol; 2015 Jul; 25(4):418-28. PubMed ID: 25407774
    [Abstract] [Full Text] [Related]

  • 33. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
    Sabha N, Knobbe CB, Maganti M, Al Omar S, Bernstein M, Cairns R, Çako B, von Deimling A, Capper D, Mak TW, Kiehl TR, Carvalho P, Garrett E, Perry A, Zadeh G, Guha A, Sidney Croul.
    Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545
    [Abstract] [Full Text] [Related]

  • 34. MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
    Zhou H, Vallières M, Bai HX, Su C, Tang H, Oldridge D, Zhang Z, Xiao B, Liao W, Tao Y, Zhou J, Zhang P, Yang L.
    Neuro Oncol; 2017 Jun 01; 19(6):862-870. PubMed ID: 28339588
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas.
    Burford C, Laxton R, Sidhu Z, Aizpurua M, King A, Bodi I, Ashkan K, Al-Sarraj S.
    Br J Neurosurg; 2019 Oct 01; 33(5):536-540. PubMed ID: 31018710
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Clinical implications of molecular analysis in diffuse glioma stratification.
    Mizoguchi M, Hata N, Kuga D, Hatae R, Akagi Y, Sangatsuda Y, Fujioka Y, Takigawa K, Funakoshi Y, Suzuki SO, Iwaki T.
    Brain Tumor Pathol; 2021 Jul 01; 38(3):210-217. PubMed ID: 34268651
    [Abstract] [Full Text] [Related]

  • 39. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.
    Ammendola S, Caldonazzi N, Simbolo M, Piredda ML, Brunelli M, Poliani PL, Pinna G, Sala F, Ghimenton C, Scarpa A, Barresi V.
    Virchows Arch; 2021 Nov 01; 479(5):987-996. PubMed ID: 34165590
    [Abstract] [Full Text] [Related]

  • 40. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers.
    Minniti G, Arcella A, Scaringi C, Lanzetta G, Di Stefano D, Scarpino S, Pace A, Giangaspero F, Osti MF, Enrici RM.
    J Neurooncol; 2014 Jan 01; 116(2):275-82. PubMed ID: 24162810
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.